Opioid treatment in pregnancy: which form is safer for Baby's brain?
NCT ID NCT03911739
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 71 babies born to mothers who took either a monthly injection or a daily tablet of buprenorphine for opioid use disorder during pregnancy. Researchers measured the babies' thinking, language, and motor skills using a standard child development test. The goal was to see if the longer-acting injection leads to better brain development than the daily tablet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
buprenorphine (extended-release injection or daily sublingual tablet)
What this could lead to
If it works, this could help doctors choose the safest opioid treatment for pregnant women to protect baby brain development.
What could go wrong
This is a small, completed sub-study (71 infants) that only observes development, not a treatment trial. Results may not apply to all babies or show clear differences between the two drug forms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addiction Recovery Services (ARS), Swedish Medical Center
Seattle, Washington, 98107, United States
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
CODA, Inc.
Portland, Oregon, 97214, United States
-
Gateway Community Services
Jacksonville, Florida, 32204, United States
-
Marshall Health MARC Program
Huntington, West Virginia, 25701, United States
-
Massachusetts General Hospital HOPE Clinic
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Pregnancy Recovery Center at Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
-
University of Utah SUPeRAD Clinic
Salt Lake City, Utah, 84108, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States